Dog · Canis lupus familiaris · typical adult weight 2.00–80.00 kg
Mitoxantrone is dosed at 5–6 mg/m2 IV q21 days in dogs, per Marquardt TM, Lindley SES, Smith AN, et al. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma. J Am Vet Med Assoc. 2019;254(2):236-242. doi:10.2460/javma.254.2.236 — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.930 (2026-08-01). — Plumb's 10th ed (held) printed p.903, Mitoxantrone monograph spanning p.902-903; page located 2026-08-05 from the book's own running heads, and carries this exact dose under the matching species heading. — SOURCE EDITION: Plumb's Veterinary Drug Handbook — ISBN 9781394172207, https://openlibrary.org/isbn/9781394172207. Mitoxantrone is used in dogs for Lymphoma, carcinomas. Routes documented in dogs: IV. A typical adult dog weighs 2.00–80.00 kg. ExoticRx lists 1 cited dose rule for Mitoxantrone in dogs, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Novantrone
| Route | Dose | Frequency | Duration | Indication | Evidence | Source |
|---|---|---|---|---|---|---|
| IV | 5–6 mg/m2 | q21 days | 4-6 cycles | Lymphoma, carcinomas | Moderate | Marquardt TM, Lindley SES, Smith AN, et al. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma. J Am Vet Med Assoc. 2019;254(2):236-242. doi:10.2460/javma.254.2.236 — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.930 (2026-08-01). — Plumb's 10th ed (held) printed p.903, Mitoxantrone monograph spanning p.902-903; page located 2026-08-05 from the book's own running heads, and carries this exact dose under the matching species heading. — SOURCE EDITION: Plumb's Veterinary Drug Handbook — ISBN 9781394172207, https://openlibrary.org/isbn/9781394172207 |
Every held source for this drug and species, as printed. Where they differ, both are shown — the choice is yours, not ours.
| Dose (mg/m2) | Route | Source | As printed |
|---|---|---|---|
| 5–5.5 | IV | Papich Saunders Handbook of Veterinary Drugs, 4th edp.568 | • 5-5.5 mg/m2 IV every 21 days, and up to 6 mg/m2 if dogs tolerate it well. |
| 6 | IV | Papich Saunders Handbook of Veterinary Drugs, 4th edp.568 | • 5-5.5 mg/m2 IV every 21 days, and up to 6 mg/m2 if dogs tolerate it well. |
Figures are transcribed from the cited page or table of each held edition and are shown for reference only. They are not dose recommendations, they do not feed the calculator, and none has been reviewed by a veterinarian.
Need the exact dose for your patient?
Enter your dog's weight to check these cited ranges in the calculator — unit and concentration math done for you.
Intercalates DNA and inhibits topoisomerase II. Related to anthracyclines but less cardiotoxic. Also disrupts RNA synthesis.
Less cardiotoxic than doxorubicin — used as alternative. Myelosuppression dose-limiting. Blue-green discoloration of urine/sclera. Safe in cats (unlike cisplatin).
Species-specific contraindications and adverse-reaction reports for dogs may differ from canine / feline reference data — consult the primary citations listed with each rule.
Mitoxantrone dose range in dogs, with cited source references: IV 5–6 mg/m2 q21 days. Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Mitoxantrone in dogs: IV.
Cited course lengths for Mitoxantrone in dogs include: 4-6 cycles. Duration depends on the indication — match it to the specific dose rule in the table above.
Mitoxantrone is indicated in dogs for: Lymphoma, carcinomas.
These are general warnings for Mitoxantrone across species; consult the dog dosing table above for species-specific guidance. Less cardiotoxic than doxorubicin — used as alternative. Myelosuppression dose-limiting. Blue-green discoloration of urine/sclera. Safe in cats (unlike cisplatin).
Why a species-specific page? Mitoxantrone pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in dogs — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.